tbuckley/cabot-search huggingface dataset:
The complete nucleotide sequences of the heavy chain variable regions of six monospecific rheumatoid factors derived from Epstein-Barr virus-transformed B cells isolated from the synovial tissue of patients with rheumatoid arthritis
Journal: Journal of Clinical Investigation (1994)

The following errors have been discovered by the authors: In the second column of page 1323, at the end of the first paragraph, the sentence "On the other hand, RF-KL1 is the only VHIH RF in this study that does not express the VHII-related idiotypes identified by the mAb B6 and D12," should read ".... RF-KL1, together with RF-TS2, are the only VHIII RFs...., In Fig. 3 A, amino acid residues 85 and 89 for RF-SJ1 should be "ACG' and "GAT," respectively, rather than "GAC" and "ACT."In Fig. 3 B, amino acid residues number 22 and 28 for GL-SJ2 should be "C" and "T," respectively, rather than "T" and " G,'" In Fig. 4, amino acid residues number 47 and 58 in GL-SJ2 should be "TGG" and "GCA," respectively, instead of "TAG" and "GTA."In Fig. 5, amino acid residue number 54 for RF-SJ2 should be "Y" rather than "E."
Alcoholics Eponymous
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
High Doses of a Corticosteroid Drug Interfere with Anticoagulant Medicines
Journal: Annals of Internal Medicine (2000)

Summaries for Patients18 April 2000High Doses of a Corticosteroid Drug Interfere with Anticoagulant MedicinesSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-8-200004180-00038 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Corticosteroid drugs (medicines related to cortisone, a substance produced by the adrenal glands) are commonly used to treat patients with inflammatory diseases or diseases of the immune system. Many of these patients also require treatment with anticoagulant drugs (“blood thinners”). Anticoagulants are used to treat or prevent blood clots (for example, in the brain [strokes], legs [thrombophlebitis], or lungs [pulmonary embolism]). Many drugs can interfere with the action of anticoagulants; some cause them to thin the blood too much, others to thin it too little. Corticosteroids have not ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Potentiation of Vitamin K Antagonists by High-Dose Intravenous Methylprednisolone”. It is in the 18 April 2000 issue of Annals of Internal Medicine (volume 132, pages 631-635). The authors are N. Costedoat-Chalumeau, Z. Amoura, G. Aymard, O. Sevin, B. Wechsler, P. Cacoub, L.T.H. Du, B. Diquet, A. Ankri, and J.-C. Piette.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPotentiation of Vitamin K Antagonists by High-Dose Intravenous Methylprednisolone Nathalie Costedoat-Chalumeau , Zahir Amoura , Guy Aymard , Odile Sevin , Bertrand Wechsler , Patrice Cacoub , Le Thi Huong Du , Bertrand Diquet , Annick Ankri , and Jean-Charles Piette Metrics 18 April 2000Volume 132, Issue 8Page: 631KeywordsAnticoagulantsAutoimmune diseasesBloodDrugsInternational normalized ratioPulmonary embolismStrokeThrombosisVeinsVitamin K ePublished: 15 August 2000 Issue Published: 18 April 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
Immune Response
Authors: Mjhinu1a Msa, F Ro, I Giorgio, A Le, France Broutet, F Cantet, H Lamouliatte, S Forestier
Journal: Gut (1995)

hay H. pylon (Hp) caus .chromcgasitis, it is sty associated with peptiC ulcer disse an recenldy it has alo bee with gstric carcinoma.Using the mvito BrdU, it has bea shown that eradicaon of Hp reduces gastic cell proliferat (1).Besides.Hp Aication dcreases ODC acdvity, the rate liming eymn m syntbesis (2).Either polyaminerescine (Put), pemidn (Spd) uad spemidine (Spm) or Epidermal Growth Factor (EGF) are inl in rgatin the celluar proliferation, both nonnal a neoplasdtc (3) Three aim ofthsstudy was to asse the effect of Hp infction on ce profaon of gastric mucosa by eauag polyamine lees m biopsy samples of the body and antum and EGF lees in biopsy ofthe ano of 11 H.p positive paticntes (5 M, 28-61 yrs and 6 F, 42-62 yrs) before and 8 weeks after eradicating therapy (DeNol tabs qid, Amoicillin qid, metronidazole 400 mg tid).After therapy H.p was eradicated in al patie The presence of Hp was evaluated by CLO test aMd histology (Wathin Stay) Polyamme levels were analyzed by HPLC.EGF levels were evluaed by ELISA.The results were anaized by Studegts t test.Poyamineare epressed as nmol/mg prot., EGF levels are oer as prot.An Body Befwe Atr p Befe Atr p Bd e bBrc~~~~f After Put 0.35±0.220.26±0.11m 0.27±0.14 0.16±0.06Spd 4.40±0.953.49±0.73* 3.48±0.71 2.93±0.64* Spm 6.94±2.23 6.29±1.57us 5.70±1.535.32±1.45as Tot 11.71±2,43 10.06±2.76 as 9.47±2.07 8.42±2.10ns SpdlSpm 0.71±0.130.54±0.16* 0.67*0.14 0.52±0.08EGF 1.07±0.65 2.23±1.52* re-p< 0.05), uS.~54i&afflOur finding show lower poamine leves and higher EGF levels in gastric biopsies taken: after therapy than in those taken before Hp eradication.This preiminay study provides new data to the assmption that Hp infection actively affcts cdlluar proliaton in gastric mucosa.
<i>Early Diagnosis of Some Serious Diseases of the Nervous System; Its Imporlance and Feasibility</i>. By E. C. Seguin, M. D., Member of the Providence Medical Association, the Association of American Physicians, etc. Reprinted from the<i>Boston Medical and Surgical Journal</i>of December 25, 1890. and February 5, 19 and 26, 1891
Journal: American Journal of Psychiatry (1891)
Life-sustaining therapies in elderly persons
Authors: P. G. Tuteur
Journal: JAMA (1990)

In a time of concern about limited health care resources, it is reasonable to question the efficacy of their use. Two studies in this issue ofThe Journalfocus on life-sustaining therapies. When is their use appropriate? Longstreth and colleagues<sup>1</sup>look at out-of-hospital cardiopulmonary resuscitation (CPR). They ask: Can the elderly benefit from this procedure? A review of all out-of-hospital cardiac arrests treated by paramedics over a recent 5-year period in Seattle, Wash, reveals that 140 persons (10%) 70 years and older were resuscitated, admitted to a hospital, and discharged alive; of these, 112 went home. From these data, Longstreth et al conclude, "Elderly patients can benefit from attempted resuscitation of out-of-hospital cardiac arrest." Also in this issue, Murphy and Matcher<sup>2</sup>explore a way to understand how life-sustaining therapies benefit patients. In an attempt to be at once critical and objective, they propose a mathematical model that quantifies
Arthritis and Rheumatism: The Diseases and Their Treatment.
Journal: Annals of Internal Medicine (1955)

Had Dr. Cyriax in this book confined his work to the subject matter of his sub-title, he would have performed a valuable service, for there are interesting points in his method of physical examination and in his elucidation of disorders of muscular function and of peri-articular lesions.As it is, we find this work one of the most exasperating that has come our way.We must admit at the outset that we were disturbed
Abortion
Authors: Dennis G. Biros
Journal: JAMA (1972)

<h3>To the Editor.—</h3> True, removal of perceived stress results in symptom relief. The results suggested that the more psychiatrically disturbed patients (ie, those with chronic psychotic and neurotic conditions) experienced less apparent relief than those patients who were considered to be more stable. This is perhaps understandable, since those patients with the more underlying stress probably experienced relatively less relief from the relatively new stress (the stressful pregnancy) than those in whom the stressful pregnancy presented itself as perhaps the most remarkable stress over a relatively more stable background. In other words, this stressful pregnancy was perhaps perceived as a pure and more clearly identifiable stress which, when removed, resulted in more dramatic symptom relief. I feel a more accurate description of the "unwanted pregnancy" would be "stressful pregnancy." It is the perceived stress implicit in the pregnancy, and what is assumed will follow, that is unwanted. Whenever stress is
White paper on the therapeutic equivalence of chemically equivalent drugs
Authors: W. B. Castle
Journal: JAMA (1969)

Recent reports of considerable variation in the serum levels, and therefore in the probable biological activities, of equal doses of certain drugs marketed by different manufacturers, focus attention upon an important determinant of drug efficacy. These variations indicate that therapeutic equivalence, or equal biological activity, cannot necessarily be inferred from equivalence in the chemical constitution of different formulations of the same drug. In the Drug Efficacy Study, it has been found that, in many cases, no data bearing on biological activity of chemically equivalent drugs are available other than those submitted by the manufacturer who originally filed a New Drug Application for his product. For this reason, the following qualifying addendum was approved by the Policy Advisory Committee of the Drug Efficacy Study and was forwarded to the Food and Drug Administration with each of the 26 groups: Drugs of identical chemical composition (so-called generic drugs) formulated and marketed by
Reply
Authors: Max Werth, Frank Gaunitz, Rolf Gebhardt
Journal: Hepatology (2007)

We thank Dr. Hakvoort and colleagues for their comments, and we appreciate the opportunity to clarify some of the points they raised. In our recent publication,1 we described the binding of STAT5 purified from liver nuclear extracts to a consensus site in the 5′-upstream enhancer of the glutamine synthetase (GS) gene in close proximity to a lymphoid enhancer factor/T cell-specific factor (LEF/TCF)-binding site. On the basis of deletion experiments in respective reporter constructs we concluded that binding of STAT5 may mediate enhancement of expression of GS, whereas the LEF/TCF site may function as a silencer of growth hormone–mediated enhancement in normal hepatocytes. This interpretation is in line with known effects of growth hormone2 and provides attractive possibilities for the cross-talk with the β-catenin signaling pathway, because LEF/TCF may act as a suppressor in the absence of β-catenin.3 The data presented for the first time by Hakvoort et al. in their letter nicely illustrate the long-known fact that growth hormone does not influence zonation of GS in liver parenchyma.2, 4 Indeed, we do not suggest that growth hormone and STAT5 might be involved in the spatial restriction of GS gene expression, because we recently published evidence that a silencer element in the first intron of the GS gene is responsible for GS zonation5 rather than the main 5′-enhancer. Furthermore, these findings make us also believe that the LEF/TCF site described by us1 may not mediate the important role of β-catenin signaling and of APC (adenomatous polyposis coli) in controlling zonation described by Benhamouche et al.6 Instead, this site may contribute to the strength of GS gene expression,7 and we maintain that growth hormone, acting via STAT5, may also influence GS mRNA levels in this way. At first glance, this view seems to contrast with the semiquantitative data of Hakvoort et al. on mRNA abundance, suggesting that either STAT5a or STAT5b, or both, are dispensable for maintaining almost normal levels of GS mRNA. However, it must be taken into account that the measurements taken by Hakvoort et al. were done in constitutive knockout mice after several weeks of age. Because of the plethora of alternative mechanisms regulating GS expression,7 it cannot be excluded that other regulatory pathways compensate for the absence of STAT5. Hakvoort et al. already referred to a possible redundancy at the STAT5 site. If so, it would be most interesting to know what mechanisms might be involved. Recently, we pointed out possible mechanistic details of the interaction of STAT5, LEF/TCF, and β-catenin, but also stressed that the structure of the GS 5′ enhancer is more complex, containing binding sites for other transcription factors as well.7 Thus, further work is needed to elucidate the full potential of this enhancer that seems to constitute an interesting precipitation point for the influence and cross-talk of several regulatory pathways. Max Werth*, Frank Gaunitz*, Rolf Gebhardt*, * Institut Für Biochemie, Medizinische Fakultät, Universität Leipzig, Leipzig, Germany.
A NEW CLINICAL ENTITY.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: A.A. Marghoob, T.G. Salopek, J. Slade, A.W. Kopf
Journal: Journal of the American Academy of Dermatology (1994)

view was the rapid improvement of his symptoms and liver enzyme elevations after discontinuation of the etretinate.The transient increase in the number of atypical lymphocytes during etretinate therapy may be an additional indication of the hypersensitivity reaction, in which antigen-driven T-cell activation is believed to be involved.
Involuntary jaw movements in elderly patients
Journal: JAMA (1977)

<h3>To the Editor.—</h3> In a recent issue ofThe Journal, Daniel M. Laskin, DDS, responded to a question regarding involuntary jaw movements in elderly patients. Although he lists three conditions that should be considered in elderly patients who manifest continuous involuntary jaw movements, there is one very important condition that he neglected to comment on: namely, tardive dyskinesia, which is quite common in elderly patients who have been receiving long-term antipsychotic drug therapy. Once the condition is established, it may be irreversible (largely depending on its duration), although numerous drugs (eg, deanol and valproate sodium) have been advocated as being efficacious in reversing this extremely disturbing syndrome. Of equal importance however, is the fact that using drugs such as benztropine (Cogentin) mesylate, trihexyphenidyl hydrochloride (Artane), and similar anticholinergic drugs are contraindicated in the treatment of tardive dyskinesia, since these medications worsen the symptoms. Similarly, agents that increase CNS dopamine levels
Bulletin of New York Acad of Medicine
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Re-analysis of 178 previously unidentifiable<i>Mycobacterium</i>isolates in the Netherlands from the 1999-2007 period
Authors: Jakko van Ingen, Rina de Zwaan, Mimount Enaimi, P.N. Richard Dekhuijzen, Martin J. Boeree, D. van Soolingen
Journal: Clinical Microbiology and Infection (2009)
Where and How to Amputate.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply:
Authors: Vlad Ratziu, Stephen Caldwell, Brent A. Neuschwander-Tetri
Journal: Hepatology (2011)

We acknowledge the pioneering work on the therapeutic value of glitazones in nonalcoholic steatohepatitis by Cusi, Harrison, Schenker, and their coworkers. We thank them for the correction related to the inclusion criteria of Belfort et al.'s study,1 and we apologize to the readers for this error in our article.2 We welcome the additional information on the calculation of the combined necroinflammation score. This information, though clearly relevant, does not appear in the online or print edition of the article, which simply refers to the Kleiner classification with no further detail. Critical details of the methodology or results should not be omitted despite the inevitable space constraints still invoked by journals in the digital era. We look forward to seeing the results of their ongoing studies, and we anticipate that the metabolic studies undertaken by them will continue to shed light on the pathogenesis of nonalcoholic steatohepatitis and potential treatment options. Vlad Ratziu M.D.*, Stephen Caldwell M.D. , Brent A. Neuschwander-Tetri M.D. , * Institut National de la Santé et de la Recherche Médicale, Unités Mixtes de Recherche en Santé 893, Hôpital Pitié Salpêtrière, (Assistance Publique Hôpitaux de Paris), Université Pierre et Marie Curie, Paris, France, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MO.
IMPORTANT PRELIMINARY WORK.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal